This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Bates, R L Articles by Frampton, G Search for Related Content PubMed PubMed Citation Articles by Bates, R L Articles by Frampton, G Social Bookmarking                         What's this?

The prevalence and clinical significance of autoantibodies to plasminogen activator inhibitor 1 in systemic lupus erythematosus

Molecular Immunology Research Group, School of Applied Sciences, University of Wolverhampton, Wulfuna Street, Wolverhampton WV1 1SB, UK

S J Payne

Molecular Immunology Research Group, School of Applied Sciences, University of Wolverhampton, Wulfuna Street, Wolverhampton WV1 1SB, UK

S L Drury

Molecular Immunology Research Group, School of Applied Sciences, University of Wolverhampton, Wulfuna Street, Wolverhampton WV1 1SB, UK

P N Nelson

Molecular Immunology Research Group, School of Applied Sciences, University of Wolverhampton, Wulfuna Street, Wolverhampton WV1 1SB, UK

D A Isenberg

Bloomsbury Rheumatology Unit, University College, London, UK

J J Murphy

Division of Life Sciences, Kings College London, SE1 9NN, UK

G Frampton

Molecular Immunology Research Group, School of Applied Sciences, University of Wolverhampton, Wulfuna Street, Wolverhampton WV1 1SB, UK, g.frampton{at}wlv.ac.uk

We have recently described the novel autoantigen plasminogen activator inhibitor (PAI-1) in systemic lupus erythematosus (SLE). The aim of this study was to determine the prevalence and clinical significance of anti-PAI-1 autoantibodiesin patients with SLE. Autoantibodies to recombinant PAI-1 were measured in retrospective sera of 48 lupus patients by immunoassay in order to assess their clinical significance. This showed that 71% of sera from 48 lupus patients had significantly elevated anti-PAI-1 autoantibodiesas compared with normal control subjects (P < 0.0001). There was a weak but significant (P < 0.043) correlation with anti-dsDNA autoantibodies. In longitudinal studies, autoantibodies against PAI-1 correlated with clinical parameters measured by the BILAG disease activity index including global clinical score. Our study demonstrates the high frequency of novel autoantibodies to PAI-1 in patients with lupus. The serial clinical correlations with anti-PAI-1 autoantibodies also support the hypothesis that these autoantibodies may play a pathogenic role in lupus.

Key Words: autoantibodies • PAI-1 • SLE

Lupus, Vol. 12, No. 8, 617-622 (2003)
DOI: 10.1191/0961203303lu436oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R Forastiero and M Martinuzzo Prothrombotic mechanisms based on the impairment of fibrinolysis in the antiphospholipid syndrome Lupus, October 1, 2008; 17(10): 872 - 877. [Abstract] [PDF]

				J D Reveille Predictive value of autoantibodies for activity of systemic lupus erythematosus Lupus, May 1, 2004; 13(5): 290 - 297. [Abstract] [PDF]